Trial Profile

A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer's Disease with Biomarkers of Inflammation

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Jul 2025 According to an INmune Bio media release,a video detailing the additional findings from the Phase 2 MINDFuL trial will be published on the companys YouTube Channel following the conclusion of Alzheimers Association International Conference (AAIC) in Toronto, Canada.
24 Jul 2025 According to an INmune Bio media release, the company anticipates submitting a publication by mid-August of the MINDFuL Phase 2 study results.
24 Jul 2025 According to an INmune Bio media release, Dr. Sharon Cohen is a site principal investigator of the MINDFuL trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com